Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2020-10-21 AGM Information
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting
AGM Information Classification · 98% confidence The document explicitly states 'Notice of Annual General Meeting' and details the date, time, and procedures for the AGM, including instructions for voting by proxy and submitting questions due to COVID-19 restrictions. This directly relates to the Annual General Meeting (AGM) process. Although it is a notice, the content is specific to the AGM event itself, making 'AGM-R' (AGM Information) the most appropriate classification over a general 'RPA' or 'RNS', as it contains the core information about the meeting structure and logistics, which is often bundled with AGM materials.
2020-10-21 English
Final Results for the year ended 30 April 2020
Earnings Release Classification · 95% confidence The document is an announcement of 'Final Results for the year ended 30 April 2020' for Scancell Holdings plc. It contains key financial highlights, operational updates, and a Chairman's statement. While it provides significant financial data and summaries, it is structured as an 'Earnings Release' (ER) announcement rather than the full audited Annual Report (10-K). It follows the standard format for a preliminary results announcement issued via RNS (Regulatory News Service) in the UK, which serves as the initial communication of annual financial performance. FY 2020
2020-10-16 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and is filed via 'RNS Number'. It details changes in voting rights percentages (from 7.92% to 6.90%) held by a shareholder (Calculus Capital Limited) in the issuer (Scancell Holdings Plc). This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2020-10-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields detailing the 'Identity of the issuer', 'Reason for the notification' (specifically 'An acquisition or disposal of voting rights'), and 'Total positions of person(s) subject to the notification obligation' showing a change in percentage holding (from 14.45% to 25.48%). This structure is characteristic of regulatory filings related to changes in significant share ownership thresholds. The RNS Number and reference to the FCA confirm its regulatory nature. This directly matches the definition for Major Shareholding Notification (MRQ).
2020-10-14 English
Posting of Circular
Capital/Financing Update Classification · 95% confidence The document is an RNS announcement (indicated by the RNS Number header and the closing statement referencing RNS, the news service of the London Stock Exchange). The content announces the 'Posting of Circular' related to a proposed investment, capital raise, and a General Meeting requiring shareholder approval. A Circular is a document sent to shareholders detailing a significant corporate action, often preceding a General Meeting. Since the document itself is an announcement *about* the posting of the Circular, and it details a significant corporate action (Capital/Financing Update), it fits best under the general regulatory announcement category, RNS, as it is not the Circular itself, nor is it a specific financial report (like 10-K or IR). However, because the core subject matter is a capital raise requiring shareholder approval (which often involves a Proxy Statement/Circular), and the document explicitly mentions the Circular contains details of the 'Capital Raise' and the 'notice of General Meeting', it strongly relates to financing activities (CAP) and shareholder voting materials (PSI). Given the document's primary function is to announce the availability of the Circular detailing a capital raise and meeting notice, and it is formatted as a standard regulatory news service release, RNS is the most appropriate general classification for the announcement itself, although it is closely related to CAP and PSI content. Given the options, RNS is the safest classification for a general regulatory news service release announcing the availability of other documents.
2020-10-13 English
Proposed investment by Redmile and Open Offer
Capital/Financing Update Classification · 98% confidence The document is an RNS announcement dated October 12, 2020, detailing a significant financing event: a £30 million investment from Redmile Group via share subscription and convertible loan notes, plus an Open Offer to raise an additional £3 million. Crucially, the document states: 'The issue of the New Convertible Loan Notes and the Open Offer are subject to the Company obtaining shareholder approval... A circular will be sent to Shareholders containing details of the Capital Raise and to convene a General Meeting...' This indicates the document is an announcement about upcoming corporate actions that require shareholder approval, which necessitates a General Meeting. The announcement itself is a regulatory filing (RNS Number: 7108B) detailing the capital raise and announcing the General Meeting date (October 29, 2020). Since it announces a General Meeting and the need for shareholder approval for the financing structure, it relates closely to the process leading up to a shareholder vote. However, the primary content is the financing details and the announcement of the meeting to approve it. Given the content focuses on the financing structure (CAP) and the announcement of a General Meeting (AGM/EGM related), the most fitting primary category is Capital/Financing Update (CAP), as the financing is the core subject, even though it triggers a meeting. If the document were solely the notice/proxy for the meeting, DEF 14A or PSI would apply, but here the financing terms dominate. Since it is a formal regulatory announcement (RNS) detailing a major capital raise, CAP is the best fit for the substance, while RNS is the format. Given the options, CAP captures the economic substance best. Alternatively, because it explicitly announces the 'Notice of General Meeting' required to approve the financing, it has elements of AGM-R or PSI, but the financing terms are the main focus. I will classify it as CAP due to the detailed terms of the subscription and loan notes, which is the primary driver of the announcement.
2020-10-12 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.